Sort
48,018 grants matching “immunotherapy”
Role of ICAM1 in development and progression of pancreatic cancer
$357,994Peter Storz · Mayo Clinic Jacksonville · R01 · FY2021 · CA
Role of Sirt2 in T Cell Metabolism
$357,994Sungjune Kim · Mayo Clinic Jacksonville · R37 · FY2025 · CA
Role of ICAM1 in development and progression of pancreatic cancer
$357,994Peter Storz · Mayo Clinic Jacksonville · R01 · FY2020 · CA
Metabolic Reprogramming of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy
$357,994Udai S Kammula · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Targeting TIGIT and PD-1 in Melanoma
$357,994Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Targeting TIGIT and PD-1 in Melanoma
$357,994Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
Metabolic Reprogramming of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy
$357,994Udai S Kammula · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA
Modulation of Angiogenesis Via the Angiostatin Receptor
$357,987Duke University · R01 · FY2002 · CA
Recognition of bacterial antigens by NKT cells
$357,972Mitchell Kronenberg · La Jolla Institute For Immunology · R01 · FY2010 · AI
Leadership, Planning and Evaluation
$357,958Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2021 · CA
Leadership, Planning and Evaluation
$357,958Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2022 · CA
Leadership, Planning and Evaluation
$357,958Taofeek K Owonikoko · University Of Maryland Baltimore · P30 · FY2024 · CA
Leadership, Planning and Evaluation
$357,958Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2023 · CA
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
$357,915Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
$357,915Jose Alejandro Guevara-Patino · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Characterizing oncogenic function of ITCH in melanoma
$357,913Lixin Wan · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Microbial- based targeting of major extracellular matrix components for improved therapy of pancreatic cancer
$357,896Edwin Manuel · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Epigenomic control of antimicrobial immunity in the intestine
$357,887Theresa Alenghat · Cincinnati Childrens Hosp Med Ctr · R01 · FY2022 · DK
Epigenomic control of antimicrobial immunity in the intestine
$357,884Theresa Alenghat · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · DK
Epigenomic control of antimicrobial immunity in the intestine
$357,880Theresa Alenghat · Cincinnati Childrens Hosp Med Ctr · R01 · FY2020 · DK
VOLT (Vanderbilt Oncology Training Program)
$357,855Douglas B Johnson · Vanderbilt University Medical Center · T32 · FY2023 · CA
Core 1: Biobank and Pathology
$357,842Asif Rashid · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA
IMMUNOREGULATION IN SCHISTOSOMIASIS
$357,831Tufts University Boston · R01 · FY2003 · AI
Targeting TIGIT and PD-1 in Melanoma
$357,804Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
Impact of CREB-driven mechanism in shaping the tumor-immune landscape
$357,796Nagaraj S. Nagathihalli · University Of Miami School Of Medicine · R01 · FY2025 · CA